Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
FHTX logo FHTX
Upturn stock ratingUpturn stock rating
FHTX logo

Foghorn Therapeutics Inc (FHTX)

Upturn stock ratingUpturn stock rating
$4.7
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: FHTX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

8 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $10.57

1 Year Target Price $10.57

Analysts Price Target For last 52 week
$10.57Target price
Low$2.94
Current$4.7
high$10.25

Analysis of Past Performance

Type Stock
Historic Profit -72.84%
Avg. Invested days 29
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 269.79M USD
Price to earnings Ratio -
1Y Target Price 10.57
Price to earnings Ratio -
1Y Target Price 10.57
Volume (30-day avg) 8
Beta 3.05
52 Weeks Range 2.94 - 10.25
Updated Date 06/30/2025
52 Weeks Range 2.94 - 10.25
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.29

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -384.96%

Management Effectiveness

Return on Assets (TTM) -23.12%
Return on Equity (TTM) -470.38%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 82381004
Price to Sales(TTM) 11.48
Enterprise Value 82381004
Price to Sales(TTM) 11.48
Enterprise Value to Revenue 3.5
Enterprise Value to EBITDA -1.21
Shares Outstanding 55741400
Shares Floating 25974922
Shares Outstanding 55741400
Shares Floating 25974922
Percent Insiders 18.95
Percent Institutions 72.7

Analyst Ratings

Rating 3
Target Price 10.57
Buy 2
Strong Buy 5
Buy 2
Strong Buy 5
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Foghorn Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Foghorn Therapeutics Inc. was founded in 2016. The company focuses on discovering and developing therapies targeting genetically determined chromatin dysregulation, a major driver of cancer.

business area logo Core Business Areas

  • Gene Traffic Controlu00ae Platform: Foghorn's proprietary drug discovery platform, Gene Traffic Controlu00ae, helps identify previously inaccessible cancer targets within the chromatin regulatory system. This platform allows for the creation of drugs against these novel targets.
  • Oncology Drug Development: Focus on developing small molecule and protein degrader drugs targeting chromatin regulatory proteins implicated in cancer. The company has several programs in preclinical and clinical development.

leadership logo Leadership and Structure

Key leadership includes CEO Michael LaCascia, and CSO Kristina Alimova. The company has a board of directors overseeing strategic direction.

Top Products and Market Share

overview logo Key Offerings

  • FOG-001: A highly selective and potent oral inhibitor of BRD9, a core member of non-canonical BAF (ncBAF) complex. Currently in Phase 1 clinical trial for relapsed and/or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Limited market share as it is in clinical trials. Competitors include companies developing other epigenetic modulators and AML/MDS therapies.
  • FOG-005: A protein degrader targeting SMARCA2, which is inactive in tumors with SMARCA4 mutations. Currently in a Phase 1 clinical trial. Competitors include other companies developing targeted therapies for SMARCA4-mutant cancers.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive, with a focus on developing novel therapies for unmet medical needs, particularly in oncology. Epigenetic therapies represent a growing segment.

Positioning

Foghorn Therapeutics is positioned as a leader in chromatin regulatory-based drug discovery and development. Its Gene Traffic Controlu00ae platform gives it a competitive advantage in identifying and drugging novel cancer targets.

Total Addressable Market (TAM)

The total addressable market for cancer therapeutics is estimated to be in the hundreds of billions of dollars. Foghorn is positioned to capture a portion of this market through its targeted therapies.

Upturn SWOT Analysis

Strengths

  • Proprietary Gene Traffic Controlu00ae platform
  • Novel target identification
  • Experienced management team
  • Strong intellectual property portfolio
  • Focus on chromatin regulation

Weaknesses

  • Early stage clinical development
  • Dependence on clinical trial success
  • High research and development costs
  • Relatively small market capitalization compared to established pharmaceutical companies

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion of pipeline into new indications
  • Advancement of clinical programs
  • Potential for breakthrough therapies
  • Growing interest in epigenetic drug targets

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from established pharmaceutical companies
  • Patent challenges
  • Changes in the regulatory landscape

Competitors and Market Share

competitor logo Key Competitors

  • EPZM
  • CLLS
  • DNLI

Competitive Landscape

Foghorn has a leading edge because of its Chromatin discovery platform compared to the other competitors in its category.

Growth Trajectory and Initiatives

Historical Growth: Historical growth will depend on clinical trial progression, partnerships, and financing. Currently no drug approvals as of 2024.

Future Projections: Future growth projections depend on the success of clinical trials and partnerships. Analyst estimates vary.

Recent Initiatives: Advancement of FOG-001 and FOG-005 clinical trials, expansion of the pipeline, and partnerships with larger companies.

Summary

Foghorn Therapeutics is a biopharmaceutical company pioneering a new class of medicines targeting chromatin dysregulation. The company's innovative platform, Gene Traffic Controlu00ae, allows it to discover novel cancer targets, giving it a competitive edge. It currently has promising compounds in Phase 1 clinical trials, representing both a great strength and weakness. Successful clinical trials and strategic partnerships are critical for future growth, however funding challenges remain a constant threat.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Foghorn Therapeutics Investor Relations
  • SEC Filings (10-K, 10-Q)
  • Industry Reports
  • Analyst Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated. Financial data requires real-time access and is unavailable for accurate population.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Foghorn Therapeutics Inc

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 2020-10-23
President, CEO & Director Mr. Adrian H. B. Gottschalk
Sector Healthcare
Industry Biotechnology
Full time employees 112
Full time employees 112

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.